InMed Pharmaceuticals Inc. (INM) Bundle
An Overview of InMed Pharmaceuticals Inc. (INM)
General Summary of InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies. The company specializes in rare and orphan diseases with a primary focus on eye diseases and pain management.
| Company Detail | Information |
|---|---|
| Founded | 2009 |
| Headquarters | Vancouver, British Columbia, Canada |
| Stock Exchange Listing | NASDAQ (INM) |
Key Product Pipeline
- INM-755 for Epidermolysis Bullosa
- INM-088 for Glaucoma
- INM-405 for Pain Management
Financial Performance (Latest Reporting Period)
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $1.2 million |
| Research & Development Expenses | $8.3 million |
| Net Loss | $12.5 million |
| Cash and Cash Equivalents | $15.6 million |
Industry Leadership Highlights
Key Competitive Advantages:
- Proprietary cannabinoid biosynthesis technology
- Advanced clinical-stage drug development
- Focus on rare disease therapeutics
InMed Pharmaceuticals continues to position itself as an innovative pharmaceutical company with a unique approach to cannabinoid-based therapeutic development.
Mission Statement of InMed Pharmaceuticals Inc. (INM)
Mission Statement of InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc. mission statement focuses on leveraging cannabinoid-based pharmaceutical development and manufacturing capabilities.
Core Mission Components
| Research Focus | Cannabinoid-based therapeutic solutions |
| Primary Therapeutic Areas | Dermatology, ophthalmology, pain management |
| R&D Investment | $3.2 million in 2023 |
Strategic Objectives
- Develop innovative cannabinoid pharmaceutical products
- Advance proprietary biosynthesis platform
- Minimize production costs through genetic engineering
Product Development Pipeline
| Lead Product INM-755 | Epidermolysis Bullosa treatment |
| Clinical Stage | Phase 2 clinical trials |
| Estimated Development Cost | $7.5 million |
Technology Platform
Biosynthesis Technology Capabilities:
- Genetic engineering of cannabinoid production
- Proprietary microbial manufacturing process
- Cost-effective cannabinoid synthesis
Financial Performance Metrics
| Annual Research Budget | $5.6 million |
| Patent Portfolio | 17 issued patents |
| Intellectual Property Investment | $2.1 million in 2023 |
Vision Statement of InMed Pharmaceuticals Inc. (INM)
Vision Statement of InMed Pharmaceuticals Inc. (INM)
Strategic Focus on Cannabinoid-Based TherapeuticsInMed Pharmaceuticals Inc. aims to develop innovative cannabinoid-based pharmaceutical products targeting specific medical conditions.
| Key Vision Components | Specific Focus Areas |
|---|---|
| Therapeutic Development | Rare and orphan diseases |
| Research Platform | Proprietary biosynthesis technology |
| Clinical Stage | INM-755 for Epidermolysis Bullosa |
InMed's vision encompasses advanced cannabinoid research utilizing proprietary biosynthesis platform.
- Targeted therapeutic development
- Precision medicine approach
- Innovative drug discovery methodology
| Program | Indication | Current Stage |
|---|---|---|
| INM-755 | Epidermolysis Bullosa | Preclinical/Clinical Development |
| INM-088 | Glaucoma | Preclinical Research |
Leveraging proprietary biosynthesis platform for cannabinoid production and pharmaceutical development.
- Advanced genetic engineering techniques
- Scalable manufacturing processes
- Consistent cannabinoid molecular structures
Core Values of InMed Pharmaceuticals Inc. (INM)
Core Values of InMed Pharmaceuticals Inc. (INM) in 2024
Innovation and Scientific ExcellenceInMed Pharmaceuticals demonstrates commitment to innovation through targeted research and development efforts.
| R&D Investment | 2024 Budget |
|---|---|
| Total R&D Expenditure | $3.2 million |
| Cannabinoid Research Allocation | $1.8 million |
- Proprietary biosynthesis platform development
- Advanced cannabinoid pharmaceutical research
- Patent portfolio expansion in pharmaceutical technologies
InMed focuses on developing targeted therapeutic treatments for unmet medical needs.
| Therapeutic Area | Current Research Focus |
|---|---|
| Epidermolysis Bullosa | INM-755 clinical development |
| Glaucoma | INM-085 preclinical research |
Maintaining high standards of corporate governance and compliance.
- Strict adherence to FDA regulatory guidelines
- Comprehensive compliance management system
- Regular external audit processes
| Sustainability Metric | 2024 Target |
|---|---|
| Carbon Footprint Reduction | 15% reduction compared to 2023 |
| Green Laboratory Practices | 100% waste recycling implementation |
Strategic partnerships and collaborative research initiatives.
- Academic research collaborations
- Industry partnerships
- International research network engagement
InMed Pharmaceuticals Inc. (INM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.